Targeted Therapy of Hepatocellular Carcinoma Using Gemcitabine-Incorporated GPC3 Aptamer

• Auteurs principaux: Jun Young Park (Auteur), Ju Ri Chae (Auteur), Ye Lim Cho (Auteur), Youndong Kim (Auteur), Dasom Lee (Auteur), Jeong Kyun Lee (Auteur), Won Jun Kang (Auteur)
• Format: Livre
• Publié: MDPI AG, 2020-10-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Hepatocellular carcinoma (HCC) is the most common malignancy of the liver, which can progress rapidly and has a poor prognosis. Glypican-3 (GPC3) has been proposed to be an important diagnostic biomarker and therapeutic target for HCC. Aptamers have emerged as promising drug delivery vehicles becaus...